Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In the dose-escalation, Phase I portion of a U.S. Phase I/II trial, MGCD0103 plus Gemzar gemcitabine produced 1
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury